4'-Bromo-4-methylaminorex (4B-MAR, 4'-Br-4-MAR) is a designer drug from the substituted aminorex family, first definitively identified in Austria in January 2022. Its pharmacological activity has not been reported, but it is believed to have stimulant effects.